Price Chart
Key Statistics
Previous Close
$34.26Day Range
52-Week Range
Avg Volume
20.9KDividend Yield
1.27%Expense Ratio
0.59%AUM
$65.1MShares Outstanding
1.3METF Grades
?ETF Grades compare this fund against others in the same category using percentile rankings across six factors. Grades range from A+ (top 5%) to F (bottom 20%). Updated daily.Sector Breakdown
| Sector | Weight % |
|---|---|
| Healthcare | 100.00% |
Country Allocation
| Country | Weight % |
|---|---|
| United States | 44.48% |
| Denmark | 18.41% |
| China | 18.28% |
| Japan | 5.28% |
| South Korea | 3.69% |
| Switzerland | 3.17% |
| United Kingdom | 3.15% |
| Hong Kong | 2.67% |
| Other | 0.86% |
Fund Information
- Issuer
- Roundhill Investments
- Category
- Healthcare
- Types
- Pharma
- Inception Date
- May 21, 2024
- Exchange
- NASDAQ
- Description
- Roundhill believes that weight loss drugs, including GLP-1 agonists, represent one of the most revolutionary advancements in the global pharmaceuticals industry. The Roundhill GLP-1 & Weight Loss ETF (“OZEM”) is the world’s first GLP-1 ETF. OZEM is an actively-managed ETF.
Similar ETFs
The Roundhill Investments - GLP-1 & Weight Loss ETF (OZEM) is an exchange-traded fund issued by Roundhill Investments that launched on May 21, 2024. It currently manages $65.1M in assets under management. The fund charges an expense ratio of 0.59%. The fund holds 29 securities in its portfolio. It falls under the Healthcare category.
Top 10 holdings represent 65.0% of the fund
| Rank | Symbol | Name | Weight % | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | 12.63% | 6,606 | $8.2M |
| 2 | NVO | Novo Nordisk A/S | 11.98% | 168,984 | $7.8M |
| 3 | PFE | Pfizer Inc | 7.08% | 165,697 | $4.6M |
| 4 | 1093.HK | CSPC Pharmaceutical Group Ltd | 6.95% | 3,728,000 | $4.5M |
| 5 | VKTX | Viking Therapeutics Inc | 4.95% | 93,822 | $3.2M |
| 6 | KLRA | Kailera Therapeutics Inc | 4.73% | 176,239 | $3.1M |
| 7 | AMGN | Amgen Inc | 4.40% | 6,634 | $2.9M |
| 8 | ZEAL.CO | Zealand Pharma A/S | 4.18% | 55,309 | $2.7M |
| 9 | 4519.T | Chugai Pharmaceutical Co Ltd | 4.16% | 60,500 | $2.7M |
| 10 | 1672.HK | Ascletis Pharma Inc | 3.90% | 1,943,000 | $2.5M |
| 11 | 128940.KS | Hanmi Pharm Co Ltd | 3.75% | 8,509 | $2.4M |
| 12 | ROP.SW | Roche Holding AG | 3.27% | 4,570 | $2.1M |
| 13 | MBX | MBX Biosciences Inc | 3.23% | 31,685 | $2.1M |
| 14 | AZN | AstraZeneca PLC | 3.19% | 12,621 | $2.1M |
| 15 | 1801.HK | Innovent Biologics Inc | 2.87% | 145,000 | $1.9M |
Detailed Returns
| Period | Return | ETF |
|---|---|---|
| 1D | -0.66% | |
| 1W | +2.66% | |
| 1M | +4.58% | |
| 3M | +7.89% | |
| 6M | +0.44% | |
| YTD | -0.87% | |
| 1Y | +32.86% | |
| 3Y | +34.17% | |
| 5Y | +34.17% |
Moving Averages
$33.15
Above 20-Day MA$32.63
Above 50-Day MA$32.64
Above 200-Day MAPrice with Moving Averages
Support & Resistance
52-Week High
$37.01
Current Price
$34.04
52-Week Low
$25.62
Current Yield
1.27%
Annual Dividend
$0.8729
Frequency
1x/year
Last Ex-Date
Dec 30, 2025
Dividend History
| Ex-Date | Amount | Pay Date |
|---|---|---|
| Dec 30, 2025 | $0.4099 | Dec 31, 2025 |
| Dec 30, 2025 | $0.4099 | Dec 31, 2025 |
| Dec 30, 2024 | $0.0531 | Dec 31, 2024 |
Dividend Payments Over Time
Category Comparison
| Metric | OZEM | Healthcare(223 ETFs) | Pharma(29 ETFs) |
|---|---|---|---|
| Fund Info | |||
| Expense Ratio | 0.59% | 0.62% | 0.66% |
| AUM | $65.1M | $1.98B | $1.78B |
| Dividend Yield | 1.27% | 3.90% | 1.82% |
| Avg Volume | 20.9K | 422.1K | 408.5K |
| Holdings | 29 | 167 | 39 |
| Performance | |||
| 1-Month Return | +7.91% | +6.56% | +8.31% |
| 6-Month Return | +7.55% | +16.09% | +23.36% |
| YTD Return | +0.32% | +16.75% | +23.65% |
| 1-Year Return | +5.44% | +15.10% | +26.72% |
Compare with Another ETF
Search for an ETF to compare with OZEM:
The Beginner's Guide to ETFs
20 pages. Zero fluff. Everything you need to start investing in ETFs.
No spam. Unsubscribe anytime.